Biotech & Biopharma
生物技术与生物医药
China's biotech sector has exploded, with hundreds of innovative biotech companies developing novel drugs, cell therapies, and gene editing technologies. Biotech parks in Suzhou, Shanghai, and Beijing rival Boston and San Francisco.
Hubs
7
cities with this sector
Total Output
¥347B
combined industry output (est.)
Companies (Est.)
2,510
across all hubs
Employment (Est.)
390K
workers in sector
Industry output is a Tech Buzz China estimate compiled from public reports; per-hub rankings are editorial. Local output, company and employment estimates have unverified observation years and may overlap across sectors. Totals may double-count hubs with overlapping sector scopes. Hub detail and sources: see the About page.
Key Statistics
Biotech companies
6,000+
2024
Source not yet linked
Out-licensing deal value
~$138B
2025
Source not yet linked
Biopharma market size
¥520B
2023
Source not yet linked
Global Context
Chinese biotech out-licensed a record ~$138B in total deal value in 2025, and roughly 40% of all assets in-licensed by big pharma globally were Chinese (PharmCube). NMPA approved a record 76 innovative drugs (47 chemical, 23 biologics, 6 traditional Chinese medicines); the US BIOSECURE Act remains a headwind.
Hub Rankings
Shanghai上海
Tier 1rapidInnovative drug development, CAR-T therapy, antibody engineering
Suzhou苏州
Tier 2rapidInnovative drugs (PD-1, ADC), CRO/CDMO, gene therapy
Wuhan武汉
Tier 2steadyVaccines, biological products, CRO/CDMO services
Guangzhou广州
Tier 2rapidRegenerative medicine, cell therapy, biosimilars
Zhuhai珠海
Tier 3emergingBiomedical devices, traditional medicine modernization, biosimilars
Chengdu成都
Tier 2rapidBiotech drugs, innovative chemical drugs, CRO/CDMO services, medical devices
Liyang溧阳
Tier 4emergingBiomanufacturing: early-stage biomedicine and medical device cluster built around Tianmuhu Health Research Institute and Jiangnan University's synthetic biology center
Policy Drivers
- 14th Five-Year Bioeconomy Plan
- MAH (Marketing Authorization Holder) reform
- Biotech park incentives
Key Companies
World's leading pharmaceutical and biotech R&D outsourcing platform, providing end-to-end drug discovery and development services.
Shanghai, Shanghai →Leading innovative biopharmaceutical company, known for PD-1 antibody and partnership with Eli Lilly.
Suzhou, Jiangsu →Pioneer in reproductive genetics and molecular diagnostics, offering next-generation sequencing-based preimplantation genetic testing.
Suzhou, Jiangsu →GenScript ProBio (Suzhou)
金斯瑞蓬勃(苏州)
Global CDMO for cell and gene therapy, with major production and development facilities in BioBay.
Suzhou, Jiangsu →BGI Genomics (South China)
BGI华大基因(华南)
Branch of the world's largest genomics organization, operating sequencing platforms and clinical testing services in the Greater Bay Area.
Guangzhou, Guangdong →